
PROSCA 2023 Satellite Symposium: Professor Alison Birtle
In this Satellite Symposium, Professor Alison Birtle (Consultant Oncologist – Rosemere Cancer Centre, Lancashire Teaching Hospitals, UK) walks through a practical approach of case studies when treating Metastatic Hormone Sensitive Prostate Cancer (HSPC) with Androgen Deprivation Therapy (ADT).
During this discussion, Professor Birtle covers the following key topics:
- Overall survival in triplet or doublet therapy
- HERO Phase III Trial results4
- Improvement to quality of life4
Recorded from PROSCA 2023, watch Professor Birtle discuss Metastatic hormone sensitive prostate cancer: When choosing treatment, why every drug matters in triplet or doublet therapy?
Watch video below

Duration : 05:25 min

Professor Alison Birtle
Professor Alison Birtle is a Consultant Clinical Oncologist at the Rosemere Cancer Centre, Lancashire Teaching Hospitals, Honorary Clinical Professor in the Faculty of Biology, Medicine & Health at the University of Manchester and Honorary Clinical Professor at The University of Central Lancashire, specialising in the treatment of urological cancers. She is advisor to Macmillan on patient information for prostate, bladder and testicular tumours, Trustee and medical advisor to Fight Bladder Cancer and Secretary to the British Uro-oncology Group. She has been Chair of the NIHR Bladder/renal Research Group, member of ESMO Educational Faculty, and in 2022 joined the EAU Guidelines Group on upper tract urothelial carcinoma and non-muscle-invasive bladder cancer.
She has published widely and lectures nationally and internationally. Prof. Birtle has been Clinical Research Lead for Lancashire and South Cumbria Cancer Research Network, Speciality Group Lead for Cancer Research for North West Coast Clinical Research Network, and Group Lead for Cancer, Surgery, Oral/Dental, and haematology for North West Coast CRN.
Prof. Birtle has been Principal Investigator and Chief Investigator on numerous urological clinical trials, and a notable Chief Investigator on the practice changing POUT trial. In 2018, she was awarded one of the national 70 stars of the NHS award by NHS England and the NHS Confederations and has won numerous prestigious awards including Researcher of the year North West Coast Health & Innovation Awards.
Orgovyx® is the One & Only Oral ADT indicated for the treatment of:1-3
- Adult patients with advanced hormone -sensitive prostate cancer
- High-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy
- High-risk localised or locally advanced hormone dependent prostate cancer as a neo-adjuvant treatment prior to radiotherapy
References:
- ORGOVYX® Summary of Product Characteristics
- Fragkoulis C, et al. Arab Journal of Urology. 2021; 19(4):460-463
- National Institute for Health and Care Excellence. British National Formulary. Available from: https://bnf.nice.org.uk/drugs. Accessed: September 2024
- Shore N D, et al. New England Journal of Medicine. 2020; 382(23):2187-2196


